Sava Infond d.o.o. Invests $346,000 in Exact Sciences Co. (NASDAQ:EXAS)

Sava Infond d.o.o. acquired a new stake in shares of Exact Sciences Co. (NASDAQ:EXAS) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 6,150 shares of the medical research company’s stock, valued at approximately $346,000.

Several other large investors have also modified their holdings of EXAS. RPg Family Wealth Advisory LLC acquired a new stake in Exact Sciences during the third quarter valued at approximately $34,000. Asset Planning Inc acquired a new stake in shares of Exact Sciences during the 4th quarter valued at approximately $40,000. Modus Advisors LLC bought a new position in Exact Sciences during the fourth quarter worth $43,000. AlphaQuest LLC boosted its holdings in Exact Sciences by 22,825.0% in the fourth quarter. AlphaQuest LLC now owns 917 shares of the medical research company’s stock worth $52,000 after purchasing an additional 913 shares during the period. Finally, SBI Securities Co. Ltd. bought a new stake in Exact Sciences during the fourth quarter valued at $66,000. Institutional investors own 88.82% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on EXAS. William Blair reaffirmed an “outperform” rating on shares of Exact Sciences in a report on Thursday, February 20th. Bank of America lowered their target price on Exact Sciences from $72.00 to $65.00 and set a “buy” rating for the company in a report on Thursday, February 20th. Piper Sandler cut their price target on Exact Sciences from $75.00 to $70.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. Royal Bank of Canada started coverage on Exact Sciences in a research note on Thursday, March 13th. They set a “sector perform” rating and a $52.00 price objective for the company. Finally, Benchmark reiterated a “buy” rating and issued a $65.00 target price on shares of Exact Sciences in a research note on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat.com, Exact Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $70.83.

Exact Sciences Price Performance

Shares of Exact Sciences stock opened at $44.99 on Friday. Exact Sciences Co. has a 52 week low of $40.62 and a 52 week high of $79.62. The company has a current ratio of 2.15, a quick ratio of 1.93 and a debt-to-equity ratio of 0.97. The company’s 50-day moving average price is $49.87 and its two-hundred day moving average price is $57.90. The stock has a market cap of $8.36 billion, a PE ratio of -8.08 and a beta of 1.25.

Exact Sciences (NASDAQ:EXAS) last released its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.23. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The business had revenue of $713.42 million during the quarter, compared to analyst estimates of $701.45 million. As a group, sell-side analysts anticipate that Exact Sciences Co. will post -0.58 EPS for the current fiscal year.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.